How heart medications affect blood flow in hypertrophic cardiomyopathy
Part of Heart & circulation clinical trials.
This study looks at how heart medications affect blood flow in people with obstructive hypertrophic cardiomyopathy. You will have a heart MRI before and after starting or adjusting treatment to see how your heart responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with obstructive hypertrophic cardiomyopathy.
- You are scheduled for or willing to have a heart MRI that checks blood flow in the heart muscle.
- You are already taking the standard medications for your condition.
- You do not have severe kidney disease, liver disease, or a history of dangerous heart rhythms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to see if the drug Mavacamten (Camzyos) helps improve blood flow to the heart muscle in people with hypertrophic obstructive cardiomyopathy (HOCM) who have chest pain or shortness of breath. If you already take Mavacamten as part of your usual care, the study will compare your PET scan results before and after treatment.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This study tests whether mavacamten, a medication that may help the heart use energy better, can improve symptoms in people with obstructive hypertrophic cardiomyopathy. It aims to see if this drug helps with chest pain and shortness of breath, and improve overall heart function.
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
This study looks at adults with a heart condition called obstructive hypertrophic cardiomyopathy. It tracks what happens after they start taking the medicine mavacamten, to learn more about its effects and how it works in real life.
This study looks at how a drug called mavacamten, which relaxes the heart muscle, works in people with obstructive hypertrophic cardiomyopathy. It uses genetic testing to try to predict who will respond best to the drug.
Hear when a new Hypertrophic Obstructive Cardiomyopathy \(HOCM\) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.